Future of the Denosumab Market: Trends, Innovations, and Key Forecasts Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Denosumab Market Size Growth Forecast: What to Expect by 2025?
The market size for denosumab has seen a swift expansion in the past few years. The market is poised to escalate from $3.27 billion in 2024 to $3.7 billion in 2025, with a compound annual growth rate (CAGR) of 13.1%. Factors attributing to growth during the historic period include advances in clinical trials and research, FDA authentications and regulatory stepping stones, increased awareness about bone health, along with strategic collaborations and promotional endeavors.

How Will the Denosumab Market Size Evolve and Grow by 2029?
Experts anticipate that the denosumab market will undergo a swift expansion in the following years, reaching an estimated value of $5.59 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 10.9%. Contributing factors to this predicted growth throughout the forecast period include an increasing number of bone metastases cases, the development of ground-breaking cancer treatments, the widespread incidence of osteoporosis, heightened osteoporosis awareness, and regulatory authorizations for new applications. Noteworthy trends during the forecast period encompass strategic alliances and partnerships, incorporation of digital health solutions, broadened indications and clinical applications, as well as notable advancements in the biosimilar development field.

View the full report here:
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

What Drivers Are Propelling the Growth of Denosumab Market Forward?
The denosumab market is predicted to experience substantial growth due to the escalating occurrence of osteoporosis. This refers to a health condition where bones weaken, leading to diminished bone density and a heightened susceptibility to fractures. Denosumab is a treatment option that halts bone resorption by targeting the RANK ligand. For example, in September 2023, data provided by the US-based governmental agency, the National Center for Biotechnology Information, from the Canadian Longitudinal Study on Aging indicated a 12.7% rate of physician-diagnosed osteoporosis and a 5.9% portion of DXA-confirmed osteoporosis in women among older adults living in communities. Concurrently, a cross-sectional study by Buttros and colleagues found a 24.6% prevalence of osteoporosis in postmenopausal women aged between 40 to 75 years, ascertained through bone mineral density (BMD) measurements. As such, the increasing occurrence of osteoporosis is fuelling the expansion of the denosumab market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Which Emerging Trends Are Transforming the Denosumab Market in 2025?
Leading firms in the denosumab market are focusing increasingly on the creation of innovative solutions such as primary treatments for osteoporosis, in a bid to gain an advantage over their competition. The term 'first-line treatment for osteoporosis' is used to denote the initial therapeutic strategy suggested by healthcare experts for patients diagnosed with osteoporosis. For example, Boan Biotech, a biotech firm based in China, gained approval for its denosumab biosimilar, Boyoubei, from the National Medical Products Administration (NMPA) of China, in November 2022. This made it the pioneer Chinese firm to produce a denosumab injection. The product is also under development for markets beyond China, such as Europe and the US, with a global marketing strategy in the pipeline. Various treatment guidelines have recommended this drug as a primary approach for managing osteoporosis. Boyoubei has the potential to significantly reduce the risk of hip, non-vertebral, and vertebral fractures in affected individuals. Moreover, Boyoubei stands as the first biosimilar to Prolia (the original creator of denosumab) to receive approval for global marketing.

What Are the Key Segments in the Denosumab Market?
The denosumab market covered in this report is segmented -

1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Who Are the Key Players Shaping the Denosumab Market's Competitive Landscape?
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

What Geographic Markets Are Powering Growth in the Denosumab Market?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.